Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) (AIM:FARN, OTC:FPHAF) (LON:FARN) chief executive Dr Markku Jalkanen joins Proactive London's Katie Pilbeam about the latest on its lead cancer asset Bexmarilimab and Traumakine, their acute respiratory distress syndrome and their financial position.
He confirms that the Bexmarilimab asset further trials will get underway in the fourth quarter and is being developed as an immunotherapy candidate for hard-to-treat forms of the disease.
Their half year results revealed company ended the six months to June 30 with €7.0mln in the bank and the firm posted a deficit for the period. The operating loss was €10.4mln.